Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 5/20 | 0.63 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.63 |
| ▸ | FNTA | P49354 | 12/20 | 0.43 |
| ▸ | FNTB | P49356 | 12/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.43 |
| ▸ | PGGT1B | P53609 | 6/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4082087 | 0.91 | CYP11B2 (0.60) | CYP11B2CYP11B1FNTAFNTBCYP19A1 | |
| SCHEMBL4086389 | 0.90 | CYP11B2 (0.59) | CYP11B2CYP11B1FNTAFNTBCYP19A1 | |
| SCHEMBL3979450 | 0.86 | CYP11B1 (0.47) | CYP11B2CYP11B1FNTAFNTBPGGT1B | |
| SCHEMBL3979748 | 0.85 | CYP11B2 (0.48) | CYP11B2CYP11B1 | |
| SCHEMBL3979124 | 0.81 | CYP11B1 (0.64) | CYP11B2CYP11B1FNTAFNTBCYP19A1 | |
| SCHEMBL4093776 | 0.80 | CYP11B1 (0.41) | CYP11B2CYP11B1 | |
| SCHEMBL3982570 | 0.80 | CYP11B2 (0.41) | CYP11B2CYP11B1 | |
| SCHEMBL3576859 | 0.80 | CYP11B1 (0.81) | CYP11B2CYP11B1FNTAFNTBCYP19A1 | |
| SCHEMBL3567225 | 0.79 | CYP11B1 (0.83) | CYP11B2CYP11B1FNTAFNTBCYP19A1 | |
| SCHEMBL3572973 | 0.78 | CYP11B1 (0.81) | CYP11B2CYP11B1FNTAFNTBCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264420-A1 | ORGANIC COMPOUNDS | KSANDER GARY MICHAEL | 2009-10-22 | — | — | US | disclosed |
| US-20090264420-A1 | ORGANIC COMPOUNDS | KSANDER GARY MICHAEL | 2009-10-22 | — | — | US | disclosed |
| US-20090264420-A1 | ORGANIC COMPOUNDS | KSANDER GARY MICHAEL | 2009-10-22 | — | — | US | disclosed |
| CN-101506216-A | Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase | NOVARTIS AG (CH) | 2009-08-12 | — | — | CN | disclosed |
| WO-2008027284-A1 | FUSED IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY ALDOSTERONE SYNTHASE AND/OR 11-BETA-HYDROXYLASE AND/OR AROMATASE | NOVARTIS AG (CH) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264420-A1 | ORGANIC COMPOUNDS | CYP17A1, CYP11B1, CYP46A1 | CYP11B2 11/4885CYP11B1 2/4885FNTA 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.